JP2020505475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505475A5 JP2020505475A5 JP2019562229A JP2019562229A JP2020505475A5 JP 2020505475 A5 JP2020505475 A5 JP 2020505475A5 JP 2019562229 A JP2019562229 A JP 2019562229A JP 2019562229 A JP2019562229 A JP 2019562229A JP 2020505475 A5 JP2020505475 A5 JP 2020505475A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- item
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 143
- 229920001184 polypeptide Polymers 0.000 claims description 125
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 125
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 125
- 239000005557 antagonist Substances 0.000 claims description 68
- 206010028980 Neoplasm Diseases 0.000 claims description 46
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 43
- 102000037865 fusion proteins Human genes 0.000 claims description 37
- 108020001507 fusion proteins Proteins 0.000 claims description 37
- 150000001413 amino acids Chemical class 0.000 claims description 36
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims description 33
- 201000011510 cancer Diseases 0.000 claims description 26
- 108010023082 activin A Proteins 0.000 claims description 19
- 239000003446 ligand Substances 0.000 claims description 13
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 claims description 10
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 10
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims description 10
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 claims description 10
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 claims description 10
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 10
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 claims description 10
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 claims description 10
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims description 10
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 claims description 10
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 claims description 10
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 claims description 10
- 108060003951 Immunoglobulin Proteins 0.000 claims description 10
- 108010023079 activin B Proteins 0.000 claims description 10
- 102000018358 immunoglobulin Human genes 0.000 claims description 10
- 239000011230 binding agent Substances 0.000 claims description 8
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 6
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 6
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 6
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 230000001394 metastastic effect Effects 0.000 claims description 6
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010062016 Immunosuppression Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 210000002865 immune cell Anatomy 0.000 claims description 3
- 230000001506 immunosuppresive effect Effects 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000021039 metastatic melanoma Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- 230000001461 cytolytic effect Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 2
- 229960002450 ofatumumab Drugs 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 20
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 claims 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 230000000771 oncological effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 157
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 39
- 239000000427 antigen Substances 0.000 description 22
- 108091007433 antigens Proteins 0.000 description 22
- 102000036639 antigens Human genes 0.000 description 22
- 244000052769 pathogen Species 0.000 description 21
- 230000001717 pathogenic effect Effects 0.000 description 20
- 230000028993 immune response Effects 0.000 description 15
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 12
- 230000002708 enhancing effect Effects 0.000 description 10
- 102100034134 Activin receptor type-1B Human genes 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 7
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 230000005924 vaccine-induced immune response Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 3
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 description 3
- 108010079292 betaglycan Proteins 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 125000003473 lipid group Chemical group 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 238000009120 supportive therapy Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 108010059616 Activins Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102100026818 Inhibin beta E chain Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022181719A JP2023012552A (ja) | 2017-02-01 | 2022-11-14 | 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453413P | 2017-02-01 | 2017-02-01 | |
| US62/453,413 | 2017-02-01 | ||
| PCT/US2018/016148 WO2018144542A1 (en) | 2017-02-01 | 2018-01-31 | TGFβ AND ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022181719A Division JP2023012552A (ja) | 2017-02-01 | 2022-11-14 | 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505475A JP2020505475A (ja) | 2020-02-20 |
| JP2020505475A5 true JP2020505475A5 (enExample) | 2021-03-11 |
| JP7246617B2 JP7246617B2 (ja) | 2023-03-28 |
Family
ID=63041217
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019562229A Active JP7246617B2 (ja) | 2017-02-01 | 2018-01-31 | 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト |
| JP2022181719A Pending JP2023012552A (ja) | 2017-02-01 | 2022-11-14 | 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022181719A Pending JP2023012552A (ja) | 2017-02-01 | 2022-11-14 | 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200306340A1 (enExample) |
| EP (1) | EP3576773B1 (enExample) |
| JP (2) | JP7246617B2 (enExample) |
| KR (1) | KR20190115037A (enExample) |
| CN (1) | CN110494155A (enExample) |
| AU (1) | AU2018214979A1 (enExample) |
| CA (1) | CA3051696A1 (enExample) |
| WO (1) | WO2018144542A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7051846B2 (ja) | 2016-11-10 | 2022-04-11 | ケロス セラピューティクス インコーポレイテッド | アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物 |
| JP7258021B2 (ja) | 2017-11-09 | 2023-04-14 | ケロス セラピューティクス インコーポレイテッド | アクチビンＩＩａ型受容体変異体を含む医薬組成物 |
| KR20200109330A (ko) | 2018-01-12 | 2020-09-22 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법 |
| CA3098679A1 (en) | 2018-05-09 | 2019-11-14 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| EP3807308A4 (en) * | 2018-06-15 | 2022-03-16 | Acceleron Pharma Inc. | BI AND TRIFUNCTIONAL FUSION PROTEINS AND THEIR USES |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| WO2022063114A1 (zh) * | 2020-09-23 | 2022-03-31 | 海正生物制药有限公司 | Tgfbr2-ecd突变体及包含其的融合蛋白与应用 |
| JP2023548399A (ja) * | 2020-11-04 | 2023-11-16 | ハン，ハック | Ｔｇｆ－ベータファミリーの複数のリガンドを阻害する能力を有する新規の二機能性多特異性アンタゴニストおよびその使用 |
| CN118109416B (zh) * | 2023-03-30 | 2024-11-22 | 广州百吉生物制药有限公司 | 功能增强型工程化免疫细胞及其制备和应用 |
| CN117721131A (zh) * | 2023-12-19 | 2024-03-19 | 吉林大学 | 一种重组骨形态发生蛋白突变体的制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1486560A3 (en) * | 1999-04-30 | 2005-02-09 | Cambridge Antibody Technology LTD | Specific antibodies and antibody fragments for TGFBETA1 |
| GB0209893D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| ES2547958T3 (es) * | 2006-12-20 | 2015-10-09 | Novarx | Vacuna de célula tumoral universal para utilización terapéutica y profiláctica anticancerígena |
| MX354099B (es) * | 2007-02-01 | 2018-02-13 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama. |
| TWI432449B (zh) * | 2007-02-02 | 2014-04-01 | Acceleron Pharma Inc | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| KR20160129095A (ko) * | 2007-02-09 | 2016-11-08 | 악셀레론 파마 인코포레이티드 | 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도 |
| CN101780272B (zh) * | 2009-12-24 | 2012-01-25 | 湖南农业大学 | 一种含有TGF β1自体疫苗制剂的应用 |
| IL323000A (en) * | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| HRP20211582T1 (hr) * | 2011-06-03 | 2022-01-07 | Xoma Technology Ltd. | Protutijela specifična za tgf-beta |
| MA41916A (fr) | 2015-04-06 | 2021-04-14 | Acceleron Pharma Inc | Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations |
| AU2016246602B2 (en) * | 2015-04-06 | 2020-11-19 | Acceleron Pharma Inc. | Single-arm type I and type II receptor fusion proteins and uses thereof |
| EP3307772B1 (en) * | 2015-06-12 | 2020-09-09 | Ludwig Institute For Cancer Research Limited | Tgf-beta 3 specific antibodies and methods and uses thereof |
| EP3420002A4 (en) * | 2016-02-22 | 2020-01-15 | Acceleron Pharma Inc. | ACTRII ANTAGONISTS FOR USE TO INCREASE IMMUNITY |
-
2018
- 2018-01-31 CN CN201880023489.0A patent/CN110494155A/zh active Pending
- 2018-01-31 US US16/482,869 patent/US20200306340A1/en not_active Abandoned
- 2018-01-31 JP JP2019562229A patent/JP7246617B2/ja active Active
- 2018-01-31 WO PCT/US2018/016148 patent/WO2018144542A1/en not_active Ceased
- 2018-01-31 CA CA3051696A patent/CA3051696A1/en active Pending
- 2018-01-31 EP EP18747362.4A patent/EP3576773B1/en active Active
- 2018-01-31 KR KR1020197025689A patent/KR20190115037A/ko not_active Ceased
- 2018-01-31 AU AU2018214979A patent/AU2018214979A1/en not_active Abandoned
-
2022
- 2022-11-14 JP JP2022181719A patent/JP2023012552A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505475A5 (enExample) | ||
| CN112480253B (zh) | 一种抗pd-l1纳米抗体及其衍生物和用途 | |
| AU2019232838B2 (en) | Methods and compositions based on ALK1 antagonists for modulating angiogenesis and pericyte coverage | |
| CN111423512B (zh) | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 | |
| JP2018503380A5 (enExample) | ||
| JP2023552851A (ja) | 二重特異性抗体およびその適用 | |
| WO2019062642A1 (zh) | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 | |
| JP6636066B2 (ja) | ヒトｐ１８５及び血管内皮増殖因子の両方を標的とする抗体及びその適用 | |
| JP6519090B2 (ja) | 血管内皮成長因子融合タンパク質 | |
| JP2017101068A5 (enExample) | ||
| JP2019506863A (ja) | Ｐｄ−ｌ１及びｋｄｒに対する二重結合タンパク質 | |
| JP2013507926A (ja) | ＩＧＦ−１Ｒ及びＥｒｂＢ３シグナル伝達を標的とする二重特異的結合剤及びその使用 | |
| CN101652387A (zh) | Alk1受体和配体拮抗剂及其用途 | |
| JP2021169475A (ja) | 高親和性抗ｖｅｇｆ抗体 | |
| JP2018501211A5 (enExample) | ||
| CN102884084A (zh) | 抗her2抗体及组合物 | |
| WO2013123861A1 (zh) | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2008508858A (ja) | マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害 | |
| CN114044827A (zh) | 低adcc/cdc功能性单抗及其制备方法与应用 | |
| JP2023531672A (ja) | Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質 | |
| US20240082394A1 (en) | Combination therapy for the treatment of cancer | |
| CN114616251B (zh) | 靶向PD-1和TGFβ的重组蛋白 | |
| JPWO2022121239A5 (enExample) | ||
| US10059756B2 (en) | Compositions comprising ALK1-ECD protein | |
| JP6887944B2 (ja) | 抗ｆｇｆｒ２抗体と他剤を含む組成物 |